{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:37:22Z","timestamp":1793165842545,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Attention-Deficit\/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder with only symptomatic care available. Genome-wide association (GWA) studies can provide a starting point in the search for novel drug targets and possibilities of drug repurposing. Here, we explored the druggable genome in ADHD by utilising GWA studies on ADHD and its co-morbid conditions. First, we explored whether the genes targeted by current ADHD drugs show association with the disorder and\/or its co-morbidities. Second, we aimed to identify genes and pathways involved in the biological processes underlying ADHD that can be targeted by pharmacological agents. These ADHD-associated druggable genes and pathways were also examined in co-morbidities of ADHD, as commonalities in their aetiology and management may lead to novel pharmacological insights. Strikingly, none of the genes encoding targets of first-line pharmacotherapeutics for ADHD were significantly associated with the disorder, suggesting that FDA-approved ADHD drugs may act through different mechanisms than those underlying ADHD. In the examined druggable genome, three loci on chromosomes 1, 4 and 12 revealed significant association with ADHD and contained nine druggable genes, five of which encode established drug targets for malignancies, autoimmune and neurodevelopmental disorders. To conclude, we present a framework to assess the druggable genome in a disorder, exemplified by ADHD. We highlight signal transduction and cell adhesion as potential novel avenues for ADHD treatment. Our findings add to knowledge on known ADHD drugs and present the exploration of druggable genome associated with ADHD, which may offer interventions at the aetiological level of the disorder.<\/jats:p>","DOI":"10.1038\/s41380-019-0540-z","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T12:39:07Z","timestamp":1571402347000},"page":"4004-4015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Druggable genome in attention deficit\/hyperactivity disorder and its co-morbid conditions. New avenues for treatment"],"prefix":"10.1038","volume":"26","author":[{"given":"Tor-Arne","family":"Hegvik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wal\u00f8en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9217-3982","authenticated-orcid":false,"given":"Stephen V.","family":"Faraone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Haavik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetyana","family":"Zayats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"540_CR1","doi-asserted-by":"crossref","first-page":"15020","DOI":"10.1038\/nrdp.2015.20","volume":"1","author":"SV Faraone","year":"2015","unstructured":"Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit\/hyperactivity disorder. Nat Rev Dis Prim. 2015;1:15020.","journal-title":"Nat Rev Dis Prim"},{"key":"540_CR2","doi-asserted-by":"crossref","unstructured":"Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2018.","DOI":"10.1038\/s41380-018-0070-0"},{"key":"540_CR3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.euroneuro.2018.08.001","volume":"28","author":"B Franke","year":"2018","unstructured":"Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018;28:1059\u201388.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl 1","key":"540_CR4","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/adc.2004.059006","volume":"90","author":"VA Harpin","year":"2005","unstructured":"Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005;90(Suppl 1):i2\u20137.","journal-title":"Arch Dis Child"},{"key":"540_CR5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cpr.2016.05.002","volume":"48","author":"C Mohr-Jensen","year":"2016","unstructured":"Mohr-Jensen C, Steinhausen HC. A meta-analysis and systematic review of the risks associated with childhood attention-deficit hyperactivity disorder on long-term outcome of arrests, convictions, and incarcerations. Clin Psychol Rev. 2016;48:32\u201342.","journal-title":"Clin Psychol Rev"},{"key":"540_CR6","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","volume":"367","author":"P Lichtenstein","year":"2012","unstructured":"Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. New Engl J Med. 2012;367:2006\u201314.","journal-title":"New Engl J Med"},{"key":"540_CR7","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(14)61684-6","volume":"385","author":"S Dalsgaard","year":"2015","unstructured":"Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385:2190\u20136.","journal-title":"Lancet"},{"key":"540_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.NPR.0000530307.76316.cf","volume":"43","author":"D Wesemann","year":"2018","unstructured":"Wesemann D, Van Cleve SN. ADHD: From childhood to young adulthood. Nurse Pract. 2018;43:8\u201315.","journal-title":"Nurse Pract"},{"key":"540_CR9","doi-asserted-by":"crossref","unstructured":"FDA-approved drugs to treat ADHD. J Psychosoc Nurs Ment Health Serv. 2018;56:13\u20134. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29505085.","DOI":"10.3928\/02793695-20180207-79"},{"key":"540_CR10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neubiorev.2018.02.001","volume":"87","author":"SV Faraone","year":"2018","unstructured":"Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit\/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255\u201370.","journal-title":"Neurosci Biobehav Rev"},{"key":"540_CR11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/tp.2017.08.02","volume":"7","author":"KA Brown","year":"2018","unstructured":"Brown KA, Samuel S, Patel DR. Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners. Transl Pediatr. 2018;7:36\u201347.","journal-title":"Transl Pediatr"},{"key":"540_CR12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/bcp.13544","volume":"84","author":"V Pauly","year":"2018","unstructured":"Pauly V, Frauger E, Lepelley M, Mallaret M, Boucherie Q, Micallef J. Patterns and profiles of methylphenidate use both in children and adults. Br J Clin Pharm. 2018;84:1215\u201327.","journal-title":"Br J Clin Pharm"},{"key":"540_CR13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0269881113482532","volume":"27","author":"DJ Heal","year":"2013","unstructured":"Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present\u2014a pharmacological and clinical perspective. J Psychopharmacol. 2013;27:479\u201396.","journal-title":"J Psychopharmacol"},{"key":"540_CR14","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/NDT.S111818","volume":"12","author":"T Sternat","year":"2016","unstructured":"Sternat T, Katzman MA. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr Dis Treat. 2016;12:2149\u201364.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"540_CR15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06540-3","volume":"9","author":"D Diogo","year":"2018","unstructured":"Diogo D, Tian C, Franklin CS, Alanne-Kinnunen M, March M, Spencer CCA, et al. Phenome-wide association studies across large population cohorts support drug target validation. Nat Commun. 2018;9:4285.","journal-title":"Nat Commun"},{"key":"540_CR16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5:727\u201338.","journal-title":"Lancet Psychiatry"},{"key":"540_CR17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jamapsychiatry.2017.1472","volume":"74","author":"Y Lu","year":"2017","unstructured":"Lu Y, Sjolander A, Cederlof M, D\u2019Onofrio BM, Almqvist C, Larsson H, et al. Association between medication use and performance on higher education entrance tests in individuals with attention-deficit\/hyperactivity disorder. JAMA Psychiatry. 2017;74:815\u201322.","journal-title":"JAMA Psychiatry"},{"key":"540_CR18","doi-asserted-by":"crossref","first-page":"e0116407","DOI":"10.1371\/journal.pone.0116407","volume":"10","author":"LE Arnold","year":"2015","unstructured":"Arnold LE, Hodgkins P, Caci H, Kahle J, Young S. Effect of treatment modality on long-term outcomes in attention-deficit\/hyperactivity disorder: a systematic review. PloS ONE. 2015;10:e0116407.","journal-title":"PloS One"},{"key":"540_CR19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.euroneuro.2012.07.016","volume":"23","author":"M Fredriksen","year":"2013","unstructured":"Fredriksen M, Halmoy A, Faraone SV, Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23:508\u201327.","journal-title":"Eur Neuropsychopharmacol"},{"key":"540_CR20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jamapsychiatry.2017.0659","volume":"74","author":"Z Chang","year":"2017","unstructured":"Chang Z, Quinn PD, Hur K, Gibbons RD, Sjolander A, Larsson H, et al. Association between medication use for attention-deficit\/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry. 2017;74:597\u2013603.","journal-title":"JAMA Psychiatry"},{"key":"540_CR21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1087054712473835","volume":"19","author":"A Rostain","year":"2015","unstructured":"Rostain A, Jensen PS, Connor DF, Miesle LM, Faraone SV. Toward quality care in ADHD: defining the goals of treatment. J Atten Disord. 2015;19:99\u2013117.","journal-title":"J Atten Disord"},{"key":"540_CR22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/jcpp.12899","volume":"60","author":"SV Faraone","year":"2018","unstructured":"Faraone SV, Rostain AL, Blader J, Busch B, Childress AC, Connor DF, et al. Practitioner review: Emotional dysregulation in attention-deficit\/hyperactivity disorder\u2014implications for clinical recognition and intervention. J Child Psychol Psychiatry Allied Discip. 2018;60:133\u201350.","journal-title":"J Child Psychol Psychiatry Allied Discip"},{"key":"540_CR23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.chi.0000199026.91699.20","volume":"45","author":"A Charach","year":"2006","unstructured":"Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry. 2006;45:415\u201321.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"540_CR24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/chi.0b013e3180686d7e","volume":"46","author":"JM Swanson","year":"2007","unstructured":"Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46:1015\u201327.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"540_CR25","first-page":"994","volume":"47","author":"SV Faraone","year":"2008","unstructured":"Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:994\u20131009.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"540_CR26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/17460441.2018.1480608","volume":"13","author":"GA Gintant","year":"2018","unstructured":"Gintant GA, George CH. Introduction to biological complexity as a missing link in drug discovery. Exp Opin Drug Discov. 2018;13:753\u201363.","journal-title":"Exp Opin Drug Discov"},{"key":"540_CR27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2017.06.005","volume":"101","author":"PM Visscher","year":"2017","unstructured":"Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet. 2017;101:5\u201322.","journal-title":"Am J Hum Genet"},{"key":"540_CR28","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/mp.2015.28","volume":"20","author":"T Lencz","year":"2015","unstructured":"Lencz T, Malhotra AK. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol Psychiatry. 2015;20:820\u20136.","journal-title":"Mol Psychiatry"},{"key":"540_CR29","doi-asserted-by":"publisher","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9. pii: eaag1166. https:\/\/doi.org\/10.1126\/scitranslmed.aag1166.","DOI":"10.1126\/scitranslmed.aag1166"},{"key":"540_CR30","first-page":"14551","volume":"2017","author":"D Demontis","year":"2018","unstructured":"Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for ADHD. Nat Genet. 2018;2017:14551\u201314543. In press: bioRxiv.","journal-title":"Nat Genet"},{"key":"540_CR31","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/ng.3931","volume":"49","author":"K Wang","year":"2017","unstructured":"Wang K, Gaitsch H, Poon H, Cox NJ, Rzhetsky A. Classification of common human diseases derived from shared genetic and environmental determinants. Nat Genet. 2017;49:1319\u201325.","journal-title":"Nat Genet"},{"key":"540_CR32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1087054716669589","volume":"22","author":"JT Instanes","year":"2018","unstructured":"Instanes JT, Klungsoyr K, Halmoy A, Fasmer OB, Haavik J. Adult ADHD and comorbid somatic disease: a systematic literature review. J Atten Disord. 2018;22:203\u201328.","journal-title":"J Atten Disord"},{"key":"540_CR33","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/ng.3888","volume":"49","author":"AR Hammerschlag","year":"2017","unstructured":"Hammerschlag AR, Stringer S, de Leeuw CA, Sniekers S, Taskesen E, Watanabe K, et al. Genome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits. Nat Genet. 2017;49:1584\u201392.","journal-title":"Nat Genet"},{"key":"540_CR34","volume":"7","author":"HA Gaspar","year":"2017","unstructured":"Gaspar HA, Breen G. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. Sci Rep. 2017;7:12460.","journal-title":"Sci Rep"},{"key":"540_CR35","doi-asserted-by":"crossref","first-page":"e1004219","DOI":"10.1371\/journal.pcbi.1004219","volume":"11","author":"CA de Leeuw","year":"2015","unstructured":"de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.","journal-title":"PLoS Comput Biol"},{"key":"540_CR36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03621-1","volume":"9","author":"AN Barbeira","year":"2018","unstructured":"Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres JM, et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. Nat Commun. 2018;9:1825.","journal-title":"Nat Commun"},{"key":"540_CR37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/bio.2015.29031.hmm","volume":"13","author":"LJ Carithers","year":"2015","unstructured":"Carithers LJ, Moore HM. The Genotype-Tissue Expression (GTEx) project. Biopreserv Biobank. 2015;13:307\u20138.","journal-title":"Biopreserv Biobank"},{"issue":"Database issue","key":"540_CR38","doi-asserted-by":"crossref","first-page":"D1049","DOI":"10.1093\/nar\/gku1179","volume":"43","author":"Gene Ontology Consortium.","year":"2015","unstructured":"Gene Ontology Consortium. Gene Ontology Consortium: going forward. Nucleic acids Res. 2015;43(Database issue):D1049\u20131056.","journal-title":"Nucleic acids Res"},{"key":"540_CR39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330.","journal-title":"Nucleic Acids Res"},{"key":"540_CR40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02244-2","volume":"9","author":"J Elia","year":"2018","unstructured":"Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, et al. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018;9:4.","journal-title":"Nat Commun"},{"key":"540_CR41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.tcb.2013.07.004","volume":"23","author":"JW Um","year":"2013","unstructured":"Um JW, Ko J. LAR-RPTPs: synaptic adhesion molecules that shape synapse development. Trends Cell Biol. 2013;23:465\u201375.","journal-title":"Trends Cell Biol"},{"key":"540_CR42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbr.2004.02.006","volume":"154","author":"MJ Kolkman","year":"2004","unstructured":"Kolkman MJ, Streijger F, Linkels M, Bloemen M, Heeren DJ, Hendriks WJ, et al. Mice lacking leukocyte common antigen-related (LAR) protein tyrosine phosphatase domains demonstrate spatial learning impairment in the two-trial water maze and hyperactivity in multiple behavioural tests. Behav Brain Res. 2004;154:171\u201382.","journal-title":"Behav Brain Res"},{"key":"540_CR43","doi-asserted-by":"crossref","first-page":"14051","DOI":"10.1523\/JNEUROSCI.1737-11.2011","volume":"31","author":"D Fisher","year":"2011","unstructured":"Fisher D, Xing B, Dill J, Li H, Hoang HH, Zhao Z, et al. Leukocyte common antigen-related phosphatase is a functional receptor for chondroitin sulfate proteoglycan axon growth inhibitors. J Neurosci: Off J Soc Neurosci. 2011;31:14051\u201366.","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"540_CR44","doi-asserted-by":"crossref","first-page":"D1068","DOI":"10.1093\/nar\/gkx1143","volume":"46","author":"KC Cotto","year":"2017","unstructured":"Cotto KC, Wagner AH, Feng YY, Kiwala S, Coffman AC, Spies G, et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 2017;46:D1068\u2013D1073.","journal-title":"Nucleic Acids Res"},{"key":"540_CR45","unstructured":"Sublingual glycine vs. placebo on attentional difficulties and hyperactivity in prepuberal children. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02655276."},{"key":"540_CR46","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0269881116658986","volume":"30","author":"RF Tzang","year":"2016","unstructured":"Tzang RF, Chang YC, Tsai GE, Lane HY. Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children. J Psychopharmacol. 2016;30:976\u201382.","journal-title":"J Psychopharmacol"},{"key":"540_CR47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2017.05.045","volume":"810","author":"S Takahashi","year":"2017","unstructured":"Takahashi S, Inamura K, Yarimizu J, Yamazaki M, Murai N, Ni K. Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3. Eur J Pharm. 2017;810:26\u201335.","journal-title":"Eur J Pharm"},{"key":"540_CR48","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1517\/13543780903002082","volume":"18","author":"CT Bever","year":"2009","unstructured":"Bever CT, Judge SI. Sustained-release fampridine for multiple sclerosis. Exp Opin Investig Drugs. 2009;18:1013\u201324.","journal-title":"Exp Opin Investig Drugs"},{"key":"540_CR49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.12512","volume":"1329","author":"AR Blight","year":"2014","unstructured":"Blight AR, Henney HR 3rd, Cohen R. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Ann N Y Acad Sci. 2014;1329:33\u201344.","journal-title":"Ann N Y Acad Sci"},{"key":"540_CR50","doi-asserted-by":"crossref","first-page":"14637","DOI":"10.1523\/JNEUROSCI.0901-09.2009","volume":"29","author":"A Miyake","year":"2009","unstructured":"Miyake A, Takahashi S, Nakamura Y, Inamura K, Matsumoto S, Mochizuki S, et al. Disruption of the ether-a-go-go K+ channel gene BEC1\/KCNH3 enhances cognitive function. J Neurosci. 2009;29:14637\u201345.","journal-title":"J Neurosci"},{"key":"540_CR51","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4103\/1673-5374.230273","volume":"13","author":"B Ucar","year":"2018","unstructured":"Ucar B, Humpel C. Collagen for brain repair: therapeutic perspectives. Neural Regen Res. 2018;13:595\u20138.","journal-title":"Neural Regen Res"},{"key":"540_CR52","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nrd913","volume":"1","author":"SR George","year":"2002","unstructured":"George SR, O\u2019Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov. 2002;1:808\u201320.","journal-title":"Nat Rev Drug Discov"},{"key":"540_CR53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1476-5381.2009.00169.x","volume":"158","author":"G Milligan","year":"2009","unstructured":"Milligan G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharm. 2009;158:5\u201314.","journal-title":"Br J Pharm"},{"key":"540_CR54","doi-asserted-by":"crossref","first-page":"a006718","DOI":"10.1101\/cshperspect.a006718","volume":"2","author":"G Neufeld","year":"2012","unstructured":"Neufeld G, Sabag AD, Rabinovicz N, Kessler O. Semaphorins in angiogenesis and tumor progression. Cold Spring Harb Perspect Med. 2012;2:a006718.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"540_CR55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ymthe.2018.10.022","volume":"27","author":"C Dupain","year":"2019","unstructured":"Dupain C, Harttrampf AC, Boursin Y, Lebeurrier M, Rondof W, Robert-Siegwald G, et al. Discovery of new fusion transcripts in a cohort of pediatric solid cancers at relapse and relevance for personalized medicine. Mol Ther. 2019;27:200\u201318.","journal-title":"Mol Ther"},{"key":"540_CR56","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4337","volume":"13","author":"T Worzfeld","year":"2014","unstructured":"Worzfeld T, Offermanns S. Semaphorins and plexins as therapeutic targets. Nat Rev Drug Discov. 2014;13:603\u201321.","journal-title":"Nat Rev Drug Discov"},{"key":"540_CR57","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41588-019-0385-z","volume":"51","author":"M Wainberg","year":"2019","unstructured":"Wainberg M, Sinnott-Armstrong N, Mancuso N, Barbeira AN, Knowles DA, Golan D, et al. Opportunities and challenges for transcriptome-wide association studies. Nat Genet. 2019;51:592\u20139.","journal-title":"Nat Genet"},{"key":"540_CR58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature14177","volume":"518","author":"AE Locke","year":"2015","unstructured":"Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197\u2013206.","journal-title":"Nature"},{"key":"540_CR59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ng.784","volume":"43","author":"H Schunkert","year":"2011","unstructured":"Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333\u20138.","journal-title":"Nat Genet"},{"key":"540_CR60","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/ng.3437","volume":"47","author":"KJ Gaulton","year":"2015","unstructured":"Gaulton KJ, Ferreira T, Lee Y, Raimondo A, Magi R, Reschen ME, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015;47:1415\u201325.","journal-title":"Nat Genet"},{"key":"540_CR61","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa0906312","volume":"363","author":"MF Moffatt","year":"2010","unstructured":"Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. New Engl J Med. 2010;363:1211\u201321.","journal-title":"New Engl J Med"},{"key":"540_CR62","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","volume":"47","author":"JZ Liu","year":"2015","unstructured":"Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979\u201386.","journal-title":"Nat Genet"},{"key":"540_CR63","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00787-017-1087-7","volume":"27","author":"TA Hegvik","year":"2017","unstructured":"Hegvik TA, Instanes JT, Haavik J, Klungsoyr K, Engeland A. Associations between attention-deficit\/hyperactivity disorder and autoimmune diseases are modified by sex: a population-based cross-sectional study. Eur Child Adolesc Psychiatry. 2017;27:677.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"540_CR64","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/ng.3424","volume":"47","author":"L Paternoster","year":"2015","unstructured":"Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47:1449\u201356.","journal-title":"Nat Genet"},{"key":"540_CR65","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature12873","volume":"506","author":"Y Okada","year":"2014","unstructured":"Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506:376\u201381.","journal-title":"Nature"},{"key":"540_CR66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1087054712474686","volume":"21","author":"MH Chen","year":"2017","unstructured":"Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, et al. Comorbidity of allergic and autoimmune diseases among patients With ADHD. J Atten Disord. 2017;21:219\u201327.","journal-title":"J Atten Disord"},{"key":"540_CR67","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.","journal-title":"PLoS Med"},{"key":"540_CR68","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41588-019-0344-8","volume":"51","author":"J Grove","year":"2019","unstructured":"Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51:431\u201344.","journal-title":"Nat Genet"},{"key":"540_CR69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/0706743717737031","volume":"63","author":"FB Diallo","year":"2018","unstructured":"Diallo FB, Fombonne E, Kisely S, Rochette L, Vasiliadis HM, Vanasse A, et al. Prevalence and Correlates of Autism Spectrum Disorders in Quebec: prevalence et correlats des troubles du spectre de l\u2019autisme au Quebec. Can J Psychiatry. 2018;63:231\u20139.","journal-title":"Can J Psychiatry"},{"key":"540_CR70","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/aur.1741","volume":"10","author":"K Supekar","year":"2017","unstructured":"Supekar K, Iyer T, Menon V. The influence of sex and age on prevalence rates of comorbid conditions in autism. Autism Res. 2017;10:778\u201389.","journal-title":"Autism Res"},{"key":"540_CR71","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng.571","volume":"42","author":"Tobacco and Genetics Consortium.","year":"2010","unstructured":"Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42:441\u20137.","journal-title":"Nat Genet"},{"key":"540_CR72","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1474-4422(14)70171-1","volume":"13","author":"International League Against Epilepsy Consortium on Complex Epilepsies.","year":"2014","unstructured":"International League Against Epilepsy Consortium on Complex Epilepsies. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol. 2014;13:893\u2013903.","journal-title":"Lancet Neurol"},{"key":"540_CR73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biopsych.2017.08.006","volume":"83","author":"I Brikell","year":"2018","unstructured":"Brikell I, Ghirardi L, D\u2019Onofrio BM, Dunn DW, Almqvist C, Dalsgaard S, et al. Familial liability to epilepsy and attention-deficit\/hyperactivity disorder: a nationwide cohort study. Biol Psychiatry. 2018;83:173\u201380.","journal-title":"Biol Psychiatry"},{"key":"540_CR74","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41588-018-0090-3","volume":"50","author":"NR Wray","year":"2018","unstructured":"Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668\u201381.","journal-title":"Nat Genet"},{"key":"540_CR75","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3598","volume":"48","author":"P Gormley","year":"2016","unstructured":"Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016;48:856\u201366.","journal-title":"Nat Genet"},{"key":"540_CR76","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics C.","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421\u20137.","journal-title":"Nature"},{"key":"540_CR77","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature17671","volume":"533","author":"A Okbay","year":"2016","unstructured":"Okbay A, Beauchamp JP, Fontana MA, Lee JJ, Pers TH, Rietveld CA, et al. Genome-wide association study identifies 74 loci associated with educational attainment. Nature. 2016;533:539\u201342.","journal-title":"Nature"},{"key":"540_CR78","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ng.3749","volume":"49","author":"JM Lane","year":"2017","unstructured":"Lane JM, Liang J, Vlasac I, Anderson SG, Bechtold DA, Bowden J, et al. Genome-wide association analyses of sleep disturbance traits identify new loci and highlight shared genetics with neuropsychiatric and metabolic traits. Nat Genet. 2017;49:274\u201381.","journal-title":"Nat Genet"},{"key":"540_CR79","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/ng.3552","volume":"48","author":"A Okbay","year":"2016","unstructured":"Okbay A, Baselmans BM, De Neve JE, Turley P, Nivard MG, Fontana MA, et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nat Genet. 2016;48:624\u201333.","journal-title":"Nat Genet"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0540-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0540-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0540-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T14:06:02Z","timestamp":1635343562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0540-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1038\/s41380-019-0540-z","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,18]]},"assertion":[{"value":"10 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"During the past three years Jan Haavik has served as a speaker at meetings organised by Eli-Lilly, HB Pharma and Shire.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}